Brenntag SE Q2 2025 Earnings Recap

Brenntag SE reported a challenging second quarter in 2025, with sales declining 4% year-over-year to EUR 3.9 billion, attributed to geopolitical tensions and demand slowdown. Operating EBITA saw a significant decrease of 14%, leading to adjusted guidance for the full year amidst ongoing pressures.

Key Takeaways

• Operating gross profit fell by 2% to EUR 974 million, with gross profit as a percentage of sales at 25.2%.
• Free cash flow generated was EUR 153 million, supporting underlying cost management amid rising operational expenses.
• The company adjusted its full-year operating EBITA forecast to EUR 950 million to EUR 1.050 billion, reflecting ongoing economic uncertainties.
• Successful acquisitions, including MCE Pharma, position Brenntag to enhance its biopharma market presence and service offerings.
• Recognition for sustainability efforts was highlighted, with a Gold rating from EcoVadis and an A- rating in the latest CDP climate assessment, underscoring commitment to environmental goals.